Supplementary Table S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Authors
Evgenia Glogova
Thomas Klingebiel (ORCID: https://orcid.org/0000-0001-5726-9092)
Supplementary Table S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Evgenia Glogova, Thomas Klingebiel, Ruth Lydia Ladenstein, Dominique Valteau‐Couanet et al.
Topics
Neuroblastoma Research and Treatments
article
Supplementary Table S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Evgenia Glogova, Thomas Klingebiel, Ruth Lydia Ladenstein, Dominique Valteau‐Couanet, Holger N. Lode, Ulrike Pötschger, Nikolai Siebert, Jean Michon, Juliet C. Gray, Adela Cañete, Roberto Luksch, Isaac Yaniv, Sascha Troschke‐Meurer, Cormac Owens, Shifra Ash, Carla Manzitti, Alberto Garaventa, Hans Loibner, John W. Anderson
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Supplementary Table S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial — Evgenia Glogova, Thomas Klingebiel, et al. · (2025) | TGRS Research Map | TGRS